Evithé Biotechnology’s Post

"The efficacy of clopidogrel depends on its conversion to an active metabolite by the cytochrome P450 2C19 (CYP2C19) enzyme. CYP2C19 poor metabolizers (PM), with two loss-of-function copies of the gene, exhibit significantly reduced enzyme activity, thereby diminishing clopidogrel's antiplatelet effect. MedicaMap™ is a pharmacogenomics solution that helps personalize medication. This solution provides information about your body’s response to 165+ medicines across 12 specialties, aiding in treatment optimization. Learn more at: https://lnkd.in/gN2f--dG #clopidogrel #pharmacogenomics #genetictesting #precisionmedicine"

Did you know that Parkinson’s disease, the world’s fastest-growing neurological disorder, currently affects 10 million people globally, with cases expected to double by 2050? To mark this year's World Parkinson's Day, we're sharing this article and infographic to pay tribute to the dedication and ingenuity of scientists who work tirelessly to understand the molecular mechanisms of this disease, and to develop and manufacture life-changing treatments. We're proud to support the Parkinson’s research and development community by providing essential research chemicals and chemical manufacturing controls. Our extensive TRC portfolio of APIs, bioactive molecules and research chemicals has been cited in nearly 2,000 Parkinson's research articles. Meanwhile, our LGC Mikromol™ pharmaceutical range provides ISO 17025-accredited API, impurity, and excipient reference materials that support the manufacture of Parkinson’s disease therapies. Find out more in our latest article: https://okt.to/wrbtWN #WorldParkinsonsDay #ParkinsonsDisease #infographic #ScienceForASaferWorld

Roche Reports the P-II (FENopta) Study Data of Fenebrutinib for Treating Relapsing Multiple Sclerosis (RMS) #roche #fenebrutinib #multiplesclerosis #clinicaltrial #phase2 #fenopta #rms #phase3 #primaryprogressivemultiplesclerosis

Did you know metabolic dysfunction-associated steatohepatitis (MASH) is caused by an excess of fat cells in the liver? Our drug candidate for MASH, entering Phase 2a clinical trials this year, has the potential to be best-in-class based on recent data we presented. Learn more here: https://brnw.ch/21wHuxk

#Antiseizure medications pose unique challenges due to their narrow therapeutic indices. Recently, D'Onofrio and colleagues provided a comprehensive expert opinion on this topic and the potential role of #pharmacogenetic testing in this context. Read the full article https://lnkd.in/eMQu7ndf or check out my structured summary here 👇

On #RareDiseaseDay, we recognize the need for continued innovation to increase treatment options and address the needs of every patient demographic across the world. There are universal challenges faced by those who live with a rare disease. - Lack of scientific knowledge and quality information on the disease. - Delays in diagnosis. - Initial misdiagnosis is common. - Heavy social and financial burdens on patients. We are proud to support accelerated development of new drugs and the #drughunters that trying to bring new hope to patients and families in need. #Research #Biotech #DrugDevelopment #CMC #CRO #CDMO

🚀 We have initiated a Phase 2 Study aimed at helping patients suffering from Irritable Bowel Syndrome (IBS). Up to 1 in 8 people suffer from #IBS type symptoms and it has a very significant healthcare and economic burden. We are evaluating our investigational medicinal product, EBX-102-02, in a multi-centre randomised double-blind placebo-controlled Ph2 clinical trial, named 'TrIuMPH' (treating IBS with an intestinal microbiota product for health). We believe that this trial could generate key data that progresses us on our quest to address the significant unmet clinical needs in IBS treatment. EBX-102-02, our next-generation full-spectrum drug candidate, holds promise in transforming the lives of IBS patients. Utilising our proprietary AMPLA™ technology and manufactured in our GMP-certified facilities in Scotland, EBX-102-02 aims to restore and fortify the #microbiome, offering a potential solution to the chronic symptoms of IBS. 🔗 Read our press release: https://lnkd.in/dyiBZJa3 🔬 Discover the TrIuMPH Study: https://lnkd.in/dPbVXYRD 🧑🔬 Learn how we are mastering the microbiome: https://lnkd.in/gAph-nvk #Biotech #LifeSciences #Innovation #GutHealth Dr James McIlroy

Seizures present a complex challenge, with potential adverse reactions from antiseizure medications adding further complexity during brain histopathology diagnostics. #Seizures #AntiseizureMedications #BrainHistopathology #MedicalChallenges

89bio Reports Commencement of the P-III (ENLIGHTEN) Study Evaluating Pegozafermin for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) #89bio #pegozafermin #metabolicdysfunctionassociatedsteatohepatitis #clinicaltrial #mash #phase3 #enlighten #fibrosis #safety #efficacy #treatment

TruVivo to become the new gold standard to study liver fibrogenic responses? Dr Kristina Wolf's recent data showcases Kupffer cell-induced fibrogenic and inflammatory responses in 2D+ hepatic system in time- and titer-dependent manner. This opens the way to using this platform as a physiologically-relevant model for MASH drug development Read more Here: https://lnkd.in/eHN4wcjN #MASH #KupfferCells #InVitro #TruVivo